about
Quantifying the Burden of Hospital-Acquired Bloodstream Infection in Children in England by Estimating Excess Length of Hospital Stay and Mortality Using a Multistate Analysis of Linked, Routinely Collected Data.The national one week prevalence audit of universal meticillin-resistant Staphylococcus aureus (MRSA) admission screening 2012.Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSAEstimating the effectiveness of isolation and decolonization measures in reducing transmission of methicillin-resistant Staphylococcus aureus in hospital general wards.Methods for estimating the burden of antimicrobial resistance: a systematic literature review protocol.A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation StudyWill co-trimoxazole resistance rates ever go down? Resistance rates remain high despite decades of reduced co-trimoxazole consumption.Measuring distance through dense weighted networks: The case of hospital-associated pathogens.Is antimicrobial stewardship cost-effective? A narrative review of the evidence.Burden, duration and costs of hospital bed closures due to acute gastroenteritis in England per winter, 2010/11-2015/16.The relative importance of large problems far away versus small problems closer to home: insights into limiting the spread of antimicrobial resistance in England.Seasonal changes in the incidence of Escherichia coli bloodstream infection: variation with region and place of onset.Does appropriate empiric antibiotic therapy modify intensive care unit-acquired Enterobacteriaceae bacteraemia mortality and discharge?Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach.Gambling with antibiotics: a novel approach for exploring antibiotic consumption decision-making.Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective.Isolation demand from carbapenemase-producing Enterobacteriaceae screening strategies based on a West London hospital network.Addressing the unknowns of antimicrobial resistance: quantifying and mapping the drivers of burden.Targeted versus universal screening and decolonization to reduce healthcare-associated meticillin-resistant Staphylococcus aureus infection.Using a longitudinal model to estimate the effect of methicillin-resistant Staphylococcus aureus infection on length of stay in an intensive care unit.Seasonality of urinary tract infections in the United Kingdom in different age groups: longitudinal analysis of The Health Improvement Network (THIN).Intensive care unit (ICU)-acquired bacteraemia and ICU mortality and discharge: addressing time-varying confounding using appropriate methodology.Estimating the opportunity costs of bed-days.Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association.Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and its Opportunity Costs for Non-Admitted Patients.Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions?Defining the appropriateness and inappropriateness of antibiotic prescribing in primary care.Actual versus 'ideal' antibiotic prescribing for common conditions in English primary care.Understanding the gender gap in antibiotic prescribing: a cross-sectional analysis of English primary care.Prevalence of resistance to antibiotics in children's urinary Escherichia coli isolates estimated using national surveillance data.Estimating the burden of antimicrobial resistance: a systematic literature review.More Research Is Needed to Quantify Risks, Benefits, and Cost-Effectiveness of Universal Mupirocin Usage.Screening suspected cases for carbapenemase-producing Enterobacteriaceae, inclusion criteria and demandQuantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling studyIdentifying English Practices that Are High Antibiotic Prescribers Accounting for Comorbidities and Other Legitimate Medical Reasons for VariationComment on 'The distribution of antibiotic use and its association with antibiotic resistance'Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelinesEfficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT).Optimising trial designs to identify appropriate antibiotic treatment durations.
P50
Q31026252-85D9AC81-6C7C-42D4-923F-23F4E71DA789Q34999038-7DC6D3F3-199A-4F8B-B0F3-E2AECF58DC26Q36298961-559A0505-3DF5-46F5-9AD4-3A6C8B5559F5Q36876511-B66A25D2-A77F-4C09-8118-ECCEE1B42204Q37400757-CCA3AA48-56BD-4569-9F09-C07771149196Q37729926-CD0725EE-2C62-46BA-BDF3-3917C6D7C1A9Q38642501-9C6F9E8B-A478-4DE7-BCA4-88627E99FC25Q38644336-420BDAA9-CCBB-46BA-9B93-A70D0CE6E200Q38667812-B6F543FA-9B4F-498F-A15A-0348E392F5C4Q38759466-1538BB7C-E2E1-4E72-B587-A083CCB20618Q38818226-B7A358E4-3144-4F4E-A0FD-A3EA7B0E572BQ38968354-75F3417B-8583-423F-BD2C-488297BEBB92Q39365884-E729DC2A-548A-4DBC-A2B5-7FCB77B1A36FQ39551108-DD7880F2-3A88-48FE-9E67-5ED93A2418C8Q40096277-BE5DAEB7-5127-4B99-95E0-CE7950AB068CQ40264565-02B95948-6874-4F58-8980-8B8B350413FDQ40466028-4BFE5938-E254-45D1-A4A9-E2D938450DBFQ40664938-0B552E1C-F37B-48B1-9EE7-CA377B447A12Q41987135-C9B487C6-6574-417D-81FA-5E2F731FC3F6Q42252660-BAD1E96B-2760-4083-9893-690A84937D6CQ43433450-57298AD4-DE26-4888-BC69-D99477BB66F4Q47424516-F99A5110-9FDF-4F57-8188-94777BC9EFFBQ47597090-2C2BD9D2-832F-4A0C-9E1C-CF26B7D12027Q47653469-E1E661D5-F639-4B98-8541-BE430D8849EEQ48501268-4D685FA4-D165-4C55-8BD8-D8D1A3BFAFAAQ51783959-9A7F675B-FDBA-4F15-B512-B929B981495EQ51784694-BED777CB-7686-41DE-ABCF-580DAB2E0A7AQ51784702-7D5D10DC-3174-414E-B931-0C2D34DBDE09Q51784708-01579C8D-4821-40B3-A329-9FA0C7B65A6BQ51785045-CB219356-4951-464E-84FB-072B86C176B3Q53687853-A2FE39E3-3953-453B-A1D0-E787B3495140Q53689673-6ED32047-4DD1-456B-946E-4C75BF68B339Q54655625-7BAE10AC-980C-4359-922B-B3AF12FCC630Q57599791-55968676-916D-43CB-AE6B-7B0E9A54D006Q58716126-902B671A-ECDF-4C6C-BBC1-7AE1C49F81E7Q63672168-C3269231-A591-4F07-9828-CD76544E14A4Q64067712-601C8960-FA4C-438A-95A5-6736E290ED73Q64093930-18121551-060F-4952-9CD2-E1E614EDA3B3Q64899765-8021BDA0-DA0F-44C2-BDD2-CEC1E25561E6Q64945737-E3618AF8-30BD-49C0-95A9-F46091333315
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Julie Robotham
@en
Julie Robotham
@nl
type
label
Julie Robotham
@en
Julie Robotham
@nl
prefLabel
Julie Robotham
@en
Julie Robotham
@nl
P31
P496
0000-0003-2515-4084